Recent Updates
Recently added Catalysts
WVE Positive Sentiment

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

Key Takeaway: Wave Life Sciences Ltd. is scheduled to host a live webcast and conference call on May 9, 2024, to review its first quarter financial results and share business updates. The event will be accessible online through their investor website. Wave specializes in RNA medicines, with a diversified pipeline targeting diseases such as Duchenne muscular dystrophy and Huntington's disease. Interested analysts can register to participate in the call, and an archived version of the webcast will be available afterward.
Price reaction · baseline $5.67 (2024-05-01 close) · hit after-hours · 1 other WVE headline(s) in the window, move may be shared
day 0 close · peak
+3.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Wave Life Sciences is focused on RNA medicines, which have broad potential for transforming health.
  • The upcoming financial results may provide insight into the company's progress and business updates.
  • Wave's diversified pipeline includes clinical programs for serious conditions, indicating a strong research focus.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
33.2%
average across 9 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
WVE-N531
Phase 2 · Duchenne Muscular Dystrophy

Full Press Release Details

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 9, 2024, to review the company’s first quarter 2024 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.

Frequently Asked Questions

When will Wave Life Sciences host the financial results call?

Wave Life Sciences will host the call on May 9, 2024, at 8:30 a.m. ET.

How can I access the live webcast of the earnings call?

The webcast can be accessed through the 'Investor Events' section on their website.

What is the focus of Wave Life Sciences?

Wave Life Sciences focuses on developing RNA medicines to improve human health.

What diseases are included in Wave's pipeline?

Wave's pipeline addresses Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and Huntington's disease.

Where is Wave Life Sciences headquartered?

Wave Life Sciences is headquartered in Cambridge, Massachusetts.

Last updated: May 2, 2024